Carisma Therapeutics (NASDAQ:CARM) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Carisma Therapeutics (NASDAQ:CARM) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock.

Separately, BTIG Research assumed coverage on shares of Carisma Therapeutics in a research report on Thursday, April 11th. They set a buy rating and a $6.00 target price on the stock.

Carisma Therapeutics Trading Up 18.8 %

Shares of CARM opened at $1.52 on Wednesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.64 and a quick ratio of 4.64. The firm has a 50 day simple moving average of $1.36 and a 200-day simple moving average of $2.04. Carisma Therapeutics has a 1-year low of $0.99 and a 1-year high of $9.77. The stock has a market cap of $63.14 million, a price-to-earnings ratio of -0.76 and a beta of 1.35.

Carisma Therapeutics (NASDAQ:CARM) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.09). Carisma Therapeutics had a negative return on equity of 215.95% and a negative net margin of 538.81%. The business had revenue of $3.40 million for the quarter, compared to analysts’ expectations of $3.90 million. Equities analysts forecast that Carisma Therapeutics will post -1.56 EPS for the current fiscal year.

Institutional Trading of Carisma Therapeutics

An institutional investor recently raised its position in Carisma Therapeutics stock. Vanguard Group Inc. raised its stake in Carisma Therapeutics, Inc. (NASDAQ:CARM) by 0.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,579,961 shares of the company’s stock after purchasing an additional 11,200 shares during the quarter. Vanguard Group Inc. owned about 3.80% of Carisma Therapeutics worth $3,587,000 at the end of the most recent quarter. 44.27% of the stock is owned by hedge funds and other institutional investors.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.